文献速递介入腹部CTDSA

多模态疗效模型预测不可切除肝细胞癌TACE-HAIC联合免疫检查点抑制剂和酪氨酸激酶抑制剂早期治疗反应

Multimodal therapeutic efficacy model for predicting early treatment response to TACE-HAIC combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in unresectable hepatocellular carcinoma.
PubMed 文献 · Eur J Radiol · 2026-03-11

本研究回顾性纳入两家独立机构的205例接受TACE-HAIC联合ICIs和TKIs治疗的不可切除肝细胞癌患者,基于增强CT影像特征、肝DSA特征和临床参数构建早期肿瘤反应预测模型。联合模型在训练队列、内部验证队列和外部验证队列的AUC分别为0.944(95%CI: 0.897-0.989)、0.916(95%CI: 0.832-0.997)和0.902(95%CI: 0.826-0.979),校准良好,决策曲线分析显示具有广泛临床实用价值。

要点

  • 联合模型整合增强CT影像组学、肝DSA特征和临床参数,预测TACE-HAIC联合ICIs和TKIs的早期肿瘤反应。
  • 外部验证队列AUC为0.902(95%CI: 0.826-0.979),校准良好,决策曲线分析显示广泛临床实用价值。
  • 模型纳入2个临床特征、9个影像组学特征和11个DSA特征。

核心结论

  • 整合肝DSA、CT影像和临床数据的多模态预测模型可用于预测不可切除肝细胞癌患者对TACE-HAIC联合TKIs和ICIs的早期肿瘤反应。

研究设计与样本

  • 回顾性纳入两家独立机构共205例接受TACE-HAIC联合ICIs和TKIs治疗的不可切除肝细胞癌患者,基于增强CT影像特征、肝DSA特征和临床参数构建早期肿瘤反应预测模型,并系统比较和评估各模型预测性能。

诊断标准与关键数值

  • 联合模型预测早期肿瘤反应的AUC在训练队列为0.944(95%CI: 0.897-0.989)。
  • 联合模型预测早期肿瘤反应的AUC在内部验证队列为0.916(95%CI: 0.832-0.997)。
  • 联合模型预测早期肿瘤反应的AUC在外部验证队列为0.902(95%CI: 0.826-0.979)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: For patients with unresectable hepatocellular carcinoma (uHCC), the novel regimen of combining transarterial chemoembolization (TACE) with hepatic arterial infusion chemotherapy (HAIC), supplemented by immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs), has brought new hope for treatment. However, individual differences are significant. Some patients do not benefit from the treatment but instead bear the toxicity of the drugs and the economic burden. Accurate prediction of early treatment responses is key to optimizing strategies.

METHODS: A total of 205 patients with uHCC who underwent TACE-HAIC combined with ICIs and TKIs therapy were retrospectively enrolled from two independent institutions. A predictive model for early tumor response was developed based on enhanced CT imaging features, hepatic digital subtraction angiography (DSA) characteristics, and clinical parameters. The predictive performance of various models was systematically compared and evaluated.

RESULTS: Two clinical features, nine radiomics features, and eleven DSA features were included in the construction of the combined model. The prediction model exhibited robust performance, with an area under the receiver operating characteristic curve (AUC) of 0.944 (95%CI: 0.897-0.989) in the training cohort, 0.916 (95%CI: 0.832-0.997) in the internal validation cohort, and 0.902 (95%CI: 0.826-0.979) in the external validation cohort. This combined model has excellent calibration, and the analysis of the decision curve shows that it has extensive clinical practical value.

CONCLUSIONS: This study developed a multimodal predictive model integrating hepatic DSA, CT imaging, and clinical data for the prediction of early tumor response to TACE-HAIC combined with TKIs and ICIs in patients with uHCC.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ou Y, Yan P, Liang T, et al. Multimodal therapeutic efficacy model for predicting early treatment response to TACE-HAIC combined with immune checkpoint inhibitors and tyrosine kinase inhibitors in unresectable hepatocellular carcinoma. Eur J Radiol. 2026. PMID: 41846065. doi:10.1016/j.ejrad.2026.112784

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。